A possible example of this is the treatment of chronic lymphocytic leukemia (CLL) with ibrutinib, a kinase inhibitor that targets BTK on the malignant B cells and ITK on the T cells [21, 22]. Here, ITK is linked to B-cell chronic lymphocytic leukemia.